Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fecal Microbiota Transplant Clear all

Conditions: Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions: CP101; Biological
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more

Conditions: Fecal Incontinence
Interventions: fecal microbial transplantation (FMT); Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: Fecal Microbiota Transplantation; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diverticulitis, Uncomplicated Diverticular Disease
Interventions: Fecal Microbiota Transplantation (FMT); Biological
Lead sponsor: Justin Maykel; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Neuroblastoma, Neuroblastoma (NB), Neuroblastoma (NBL), Neuroblastoma (Measurable Disease), Neuroblastoma Recurrent, Neuroblastoma in Children, Neuroblastoma. CNS
Interventions: Fecal Microbial Transplantation; Biological
Lead sponsor: ProgenaBiome; Other
Eligibility: 5 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Ventura, California

Conditions: Recurrent Clostridium Difficile Infection
Interventions: RBX2660 (microbiota suspension); Biological
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more

Conditions: Ulcerative Colitis
Interventions: Fecal Microbial Transplant; Biological
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 7 Years to 21 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Questionnaire Administration, Resection, Therapeutic Colonoscopy; Procedure · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection, Methicillin-resistant Staphylococcus Aureus
Interventions: PMT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Pouchitis
Interventions: Biologically active human fecal material, OpenBiome; Drug
Lead sponsor: Najwa Elnachef; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nonalcoholic Fatty Liver Disease
Interventions: Fecal Microbiota Transplantation; Drug
Lead sponsor: Lifespan; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Active C. Difficile Colitis
Interventions: Microbiota Transplantation (FMT); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2036
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions: Fecal Microbiota Transplantation (FMT); Biological
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Years to 22 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Clostridium Difficile Infection
Interventions: Microbiota Enrichment Program (MEP); Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Recurrent C. Difficile Infection
Interventions: Fecal microbiota transplantation ± bezlotoxumab; Drug
Lead sponsor: Alexander Khoruts; Other
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP)
Interventions: Tributyrin, Placebo; Drug
Lead sponsor: Prabesh Kanel; Other
Eligibility: 45 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Irritable Bowel Syndrome
Interventions: fecal microbiota transplantation, placebo fecal microbiota transplantation, FMT with antibiotic pre-treatment (v1), FMT with antibiotic pre-treatment (v2); Procedure · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clostridium Difficile Infection
Interventions: Human fecal matter; Biological
Lead sponsor: Englewood Hospital and Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: Fecal Microbiota Transplant; Biological
Lead sponsor: Judith Kelsen; Other
Eligibility: 3 Years to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV
Interventions: Fecal Microbiota; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: Fecal microbiota transplant, Pembrolizumab, Enzalutamide; Biological · Drug
Lead sponsor: Julie Graff, MD; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Crohn's Disease
Interventions: Fecal Microbial Transplantation; Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adults With Ulcerative Colitis
Interventions: PRIM-DJ2727, Placebos; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastro-Intestinal Disorder
Interventions: Fecal microbiota transplant (FMT); Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women

Fecal Microbiota Transplantation for Ulcerative Colitis

FMT in Uncomplicated Diverticulitis

Fecal Microbiota Transplant for Neuroblastoma in a Single Patient

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

PMT for MDRO Decolonization

Fecal Microbiota Transplant (FMT) for Pouchitis

Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

Fecal Microbiota Transplantation in Pediatric Patients

A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program

Rescue FMT with Bezlotoxumab for Recurrent C. Difficile Infection

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS

Fecal Microbiota Transplantation for C Diff Infection

Fecal Microbiome Transplant

Fecal Microbiota Transplantation in HIV

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).